Tycel Phillips, M.D.

(877) 460-4673
Tycel Phillips, M.D.
Hematologist-Oncologist
Clinical Expertise
  • Hematology
  • Lymphoma (CLL, DLBCL, Hodgkin)
Research Area
  • Hematology and Hematopoietic Cell Transplantation
Academic Appointments
  • Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Hematology & Hematopoietic Cell Transplantation
Lymphoma

Cancer care is a sort of personal mission for Tycel Phillips, M.D.

As a teen, he saw how pancreatic cancer affected his grandmother and decided to follow her example of service and make his career helping others as a physician. When he was a medical resident, he lost his mother to breast cancer; her experience with chemotherapy inspired him to pursue research into treatments that are less toxic for patients.

His approach to patients is to listen first to understand their needs and develop the most beneficial treatment plan.

Dr. Phillips earned his medical degree from Rush University, followed by a residency in internal medicine at the John H. Stroger Jr. Hospital of Cook County in Chicago. His fellowship training in oncology/hematology took place at University Hospitals in Cleveland. Before joining City of Hope®, he was a clinical associate professor at the University of Michigan, where he was appointed the Maria Reinhardt DeCesare Research Professor of Blood Cancers and Bone Marrow Transplantation.

Leading clinical trials into new targeted therapies is a vital part of Dr. Phillips’ work. He has published over 40 peer-reviewed studies and attracted dozens of research grants.

Away from work, Dr. Phillips likes to read, ride his bicycle with his children, exercise and travel.

Location

Education & Experience

Board Certifications

  • American Board of Internal Medicine-Medical Oncology
  • American Board of Internal Medicine-Hematology

Degrees

  • 2006, Doctor of Medicine, Rush University, Chicago, Illinois
  • 2001, Bachelor of Science, University of Illinois, Urbana-Champaign, Illinois

Fellowship

  • 2012, Fellowship, Hematology and Oncology, University Hospitals, Cleveland, Ohio

Residency

  • 2009, Residency, Internal Medicine, John H. Stroger Hospital of Cook County, Chicago, Illinois

Internship

  • 2007, Internship, Internal Medicine, John H. Stroger Hospital of Cook County, Chicago, Illinois

Professional Experience

  • 2022-Present, Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation, Division of Lymphoma, City of Hope, Duarte, California
  • 2021-2022, Maria Reinhardt DeCesare Research Professor of Blood Cancers and Bone Marrow Transplantation, Michigan Medicine, Ann Arbor, Michigan
  • 2020-2021, Clinical Associate Professor, Internal Medicine, Hematology/Oncology, University of Michigan-Ann Arbor, Ann Arbor, Michigan
  • 2015-2020, Clinical Assistant Professor, Internal Medicine, Hematology/Oncology, University of Michigan-Ann Arbor, Ann Arbor, Michigan

Memberships

  • 2023-Present, Member, European Hematology Association
  • 2022-Present, Member, SITC Committee
  • 2021-Present, Member, MSHO
  • 2014-Present, Member, SWOG
  • 2014-Present, Member, Big10 Cancer Research Consortium
  • 2011-Present, Member, American Association for Cancer Research
  • 2009-Present, Member, American Society of Hematology
  • 2009-Present, Member, American Society of Clinical Oncology
  • 2002-2006, Member, Student National Medical Association

Publications

View all publications

  • Phillips TJ, Carlo-Stella C, Morschhauser F, Bachy E, Crump M, Trněný M, Bartlett NL, Zaucha J, Wrobel T, Offner F, Humphrey K, Relf J, Filézac de L'Etang A, Carlile DJ, Byrne B, Qayum N, Lundberg L, Dickinson M. Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study. J Clin Oncol. 2025 Jan 20;43(3):318-328. doi: 10.1200/JCO.23.02470. Epub 2024 Oct 4. PMID: 39365960; PMCID: PMC11771347.
  • Westin J, Phillips TJ, Mehta A, Hoffmann MS, Gonzalez-Barca E, Thieblemont C, Bastos-Oreiro M, Greil R, Giebel S, Wei MC, Wang J, Bucher R, Sit J, Penuel E, Purev E, Yee DL, Bergua-Burgues JM. Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study. Blood Adv. 2025 May 27;9(10):2461-2472. doi: 10.1182/bloodadvances.2024014907. PMID: 39908481; PMCID: PMC12143814.
  • Kordic A, Phillips TJ, Weiss J. The Current State of Bispecific Antibodies and T-Cell Directed Therapy in NHL. Cancers (Basel). 2025 Mar 31;17(7):1192. doi: 10.3390/cancers17071192. PMID: 40227768; PMCID: PMC11988123.
  • Olszewski AJ, Phillips TJ, Hoffmann MS, Armand P, Kim TM, Yoon DH, Mehta A, Greil R, Westin J, Lossos IS, Munoz JL, Sit J, Wei MC, Yang A, Chen V, Purev E, Yee DL, Jaeger U. Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. Blood Adv. 2023 Oct 24;7(20):6055-6065. doi: 10.1182/bloodadvances.2023010840. PMID: 37581593; PMCID: PMC10582312.
  • Xiao A, Chen L, Pak S, Lee B, Mei M, Budde E, Siddiqi T, Godfrey J, Herrera A, Kallam A, Phillips T, Baird JH, Borogovac A, Kwak L, Rosen ST, Danilov A, Dadwal S, Shouse G, Thiruvengadam SK. Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphoma. Leuk Lymphoma. 2025 Dec;66(12):2260-2268. doi: 10.1080/10428194.2025.2540442. Epub 2025 Aug 5. PMID: 40765130.
  • Othman T, Baird JH, Wang Y, Pak S, Zhong H, Aldoss I, Cai JL, Danilov A, Phillips TJ, Agrawal V, Sandhu KS, Mei M, Koller PB, Palmer J, Forman SJ, Budde LE, Aribi A. Outpatient Brexucabtagene Autoleucel in B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma. Am J Hematol. 2025 Oct;100(10):1916-1919. doi: 10.1002/ajh.70038. Epub 2025 Aug 20. PMID: 40833241.
  • Lopedote P, Shouse G, Puverel S, Muir A, Roleder C, Sportelli P, Miskin H, Chen L, Phillips TJ, Danilov AV. A chemotherapy-free regimen of acalabrutinib, umbralisib and ublituximab achieved high response rates and undetectable minimal residual disease in patients with untreated mantle cell lymphoma. Br J Haematol. 2025 May;206(5):1497-1501. doi: 10.1111/bjh.20041. Epub 2025 Apr 2. PMID: 40176303.
  • Weiss JM, Phillips TJ. SOHO State of the Art Updates and Next Questions | The Current State of CAR T-Cell Therapy and Bispecific Antibodies in Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2025 May;25(5):304-308. doi: 10.1016/j.clml.2024.10.009. Epub 2024 Oct 16. PMID: 39523133.

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
4.9
Recommend this provider office
4.9
Provider explain in way you understand
4.9
Provider listen carefully to you
4.9
Show respect for what you say
4.9
Spend enough time with you
4.9
Rate provider 0-10
4.8
Know important info medical history
03/22/26
Wonderful doctor. SO intelligent, sharing of recent research on MCL, enjoys educating us about his fabulous research [...] and a very genuine person. - Verified patient
03/18/26
Excellent - Verified patient
03/04/26
They inspire confidence, security and help you - Verified patient
03/04/26
If it is very different all the service faster in all excellent the service thank you - Verified patient
01/31/26
The team has been excellent in providing the care and have been attentive. - Verified patient